The introduction of Academy of Managed Care Pharmacy guidelines, which provide a format for the submission of dossiers by pharmaceutical manufacturers to pharmacy and therapeutics committee, has changed the market dynamics of the pharmaceutical industry. These guidelines, though voluntary, change the focus from efficacy, safety and acquisition cost to that of demonstrating a product’s overall value. Consequently, product managers now must use patient reported outcomes and pharmacoeconomic data to establish the overall value of their products.This trend has important implications to the bottom line of pharmaceutical companies. Pharmacoeconomic data can help to quantify the economic impact of new pharmacological treatments on overall treatment costs.

The Institute for International Research is pleased to bring you the 2nd Annual Pharmaceutical Outcomes Research conference. Our 2nd annual event offers product managers and health economic professionals solutions to develop AMCP compliant dossiers and pharmacoeconomic data analysis techniques that establish value proposition for their products.By establishing a value proposition for new pharmacological treatments you increase opportunity for access to formulary placement and greater revenues. The mission of this conference is to help pharmaceutical companies achieve greater return-on-investment from their outcomes research efforts and offers solutions to increase utilization for a drug by demonstrating the product’s value in terms of cost and quality of life.

Shape of the Agenda

On Day One of the conference extend your outcomes research education by participating in the pre-conference workshop, Using Health Outcomes to Maximize the Potential of Your Patient Registry. Ensure that you know the strategies for designing, collecting and interpreting health outcomes in registries that maximize the bridge between clinical and commercial objectives. Gain insights on why registries are gaining recognition as a valuable tool to position products in an increasing competitive market and how health outcomes can play a critical role by enriching registry data and optimizing the investment of resources.

Day One continues with our first keynote discussion given by Dr. Louis M. Sherwood, President of Medsa and former Senior Vice President of US Medical and Scientific Affairs for Merck, who while at Merck was responsible for developing their outcomes research program. Monday afternoon you hear presentations given by Centocor, Pfizer, Foundation for Managed Care Pharmacy (AMCP), Parexel, Janssen and PharmMetrics.

On Day Two of the conference, we open with our second keynote discussion from C. Daniel Mullins from the University of Maryland School of Pharmacy discussing translating clinical outcomes into economic outcomes.Then hear from The Brod Group,AstraZeneca LP, Healthbridge and Ludbeck.After having lunch with your colleagues, you spend the remaining portion of the conference hearing from Novartis Pharmaceuticals Corporation, Avalon Health Solutions, Thoratec Corporation, CMS, AstraZeneca Sweden, MAPI Research Institute, Paris Hospitals, Forest Research Institute and from Louis Morris.

Key Opportunity to Network

Meet our distinguished speaking faculty during coffee and refreshment breaks as well as luncheons, panel discussions and Q&A sessions. Don’t miss this unique opportunity to talk one-on-one with our speaking facility and meet with industry colleagues. In addition to these networking opportunities, you receive a copy of the conference documentation, a valuable tool to take back to your office for future reference.